The problems of antibiotic resistance in cystic fibrosis and solutions

Expert Review of Respiratory Medicine

Volumn 9, Issue 1, 2015, Pages 73-88

  López Causapé, Carla ^a   Rojo Molinero, Estrella ^a   MacIà, Mariá D ^a   Oliver, Antonio ^a  

^a HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

Author keywords

Biofilms; combined treatment; cystic fibrosis; epidemic strains; hypermutation; infection control; multidrug resistance; PK PD parameters; Pseudomonas aeruginosa; Sequential treatment

Indexed keywords

2 AMINOIMIDAZOLE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZITHROMYCIN; BACTERIAL DNA; BETA LACTAM ANTIBIOTIC; CEFEPIME; CEFOTAXIME; CEFTAZIDIME; CIPROFLOXACIN; COLISTIN; COTRIMOXAZOLE; DEOXYRIBONUCLEASE; FOSFOMYCIN; FURANONE DERIVATIVE; IMIDAZOLE DERIVATIVE; IMIPENEM; LEVOFLOXACIN; MACROLIDE; MANOALIDE; MEROPENEM; MINOCYCLINE; PATULIN; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SOLENOPSIN A; TOBRAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRULENCE FACTOR; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; BACTERIAL STRAIN; BACTERIOPHAGE; BIOFILM; CHRONIC DISEASE; CYSTIC FIBROSIS; DRUG EFFICACY; EPIDEMIC; GARLIC; GEOGRAPHIC DISTRIBUTION; GINSENG; HORIZONTAL GENE TRANSFER; HUMAN; HYPERMUTATION; INFECTION CONTROL; IRON METABOLISM; LUNG FUNCTION; LUNG INFECTION; MAXIMUM PLASMA CONCENTRATION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; MUTATION; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; QUORUM SENSING; RECOMMENDED DRUG DOSE; RESPIRATORY TRACT INFECTION; REVIEW; ANIMAL; COMPLICATION; DRUG EFFECTS; GENETICS; GENOTYPE; GROWTH, DEVELOPMENT AND AGING; LUNG; MICROBIOLOGY; PATHOPHYSIOLOGY; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; BIOFILMS; CHRONIC DISEASE; CYSTIC FIBROSIS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENOTYPE; HUMANS; LUNG; MUTATION; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; RESPIRATORY TRACT INFECTIONS;

EID: 84920982557     PISSN: 17476348     EISSN: 17476356     Source Type: Journal    
DOI: 10.1586/17476348.2015.995640     Document Type: Review

References (127)

1. O'Sullivan BP, Freedman SD. Cystic fibrosis. Lancet 2009;373(9678):1891-904
2. Hampton TH, Green DM, Cutting GR, et al. The microbiome in pediatric cystic fibrosis patients: the role of shared environment suggests a window of intervention. Microbiome 2014;28:2-14
3. Hoegger MJ, Fischer AJ, McMenimen JD, et al. Cystic fibrosis. Impaired mucus detachment disrupts mucociliary transport in a piglet model of cystic fibrosis. Science 2014;345(6198):818-22
4. Cystic fibrosis foundation patient registry. 2012 Annual data report. Cystic Fibrosis Foundation; Bethesda, MD
5. Emerson J, McNamara S, Buccat AM, et al. Changes in cystic fibrosis sputum microbiology in the United States between 1995 and 2008. Pediatr Pulmonol 2010; 45(4):363-70.
6. LiPuma JJ. The changing microbial epidemiology in cystic fibrosis. Clin Microbiol Rev 2010;23(2):299-323
7. Goss CH, Muhlebach MS. Review: staphylococcus aureus and MRSA in cystic fibrosis. J Cystic Fibros 2011;10(5):298-306
8. Lechtzin N, John M, Irizarry R, et al. Outcomes of adults with cystic fibrosis infected with antibiotic-resistant Pseudomonas aeruginosa. Respiration 2006; 73(1):27-33
9. Ren CL, Konstan MW, Yegin A, et al. Multiple antibiotic-resistant Pseudomonas aeruginosa and lung function decline in patients with cystic fibrosis. J Cyst Fibros 2012;11(4):293-9
10. Stewart PS, Costerton JW. Antibiotic resistance of bacteria in biofilms. Lancet 2001;358(9276):135-8
11. Høiby N, Bjarnsholt T, Givskov M, et al. Antibiotic resistance of bacterial biofilms. Int J Antimicrob Agents 2010;35(4):322-32.
12. O'Toole G, Kaplan HB, Kolter R. Biofilm formation as microbial development. Annu Rev Microbiol 2000;54:49-79
13. Cucarella C, Solano C, Valle J, et al. Bap, a Staphylococcus aureus surface protein involved in biofilm formation. J Bacteriol 2001;183(9):2888-96
14. Bjarnsholt T, Jensen PØ, Fiandaca MJ, et al. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients. Pediatr Pulmonol 2009;44(6): 547-58
15. Worlitzsch D, Tarran R, Ulrich M, et al. Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients. J Clin Invest 2002;109(3):317-25
16. Flemming HC, Wingender J. The biofilm matrix. Nat Rev Microbiol 2010;8(9): 623-33
17. Whitchurch CB, Tolker-Nielsen T, Ragas PC, Mattick JS. Extracellular DNA required for bacterial biofilm formation. Science 2002;295(5559):1487
18. Bjarnsholt T, Ciofu O, Molin S, et al. Applying insights from biofilm biology to drug development-can a new approach be developed? Nat Rev Drug Discov 2013; 12(10):791-808
19. Boyd A, Chakrabarty AM. Role of alginate lyase in cell detachment of Pseudomonas aeruginosa. Appl Environ Microbiol 1994; 60(7):2355-9
20. Pamp SJ, Tolker-Nielsen T. Multiple roles of biosurfactants in structural biofilm development by Pseudomonas aeruginosa. J Bacteriol 2007;189(6):2531-9
21. Kolpen M, Bjarnsholt T, Moser C, et al. Nitric oxide production by polymorphonuclear leucocytes in infected cystic fibrosis sputum consumes oxygen. Clin Exp Immunol 2014;177(1):310-19
22. Bjarnsholt T, Alhede M, Alhede M, et al. The in vivo biofilm. Trends Microbiol 2013;21(9):466-74
23. Lewis K. Multidrug tolerance of biofilms and persister cells. Curr Top Microbiol Immunol 2008;322:107-31
24. Alipour M, Suntres ZE, Omri A. Importance of DNase and alginate lyase for enhancing free and liposome encapsulated aminoglycoside activity against Pseudomonas aeruginosa. J Antimicrob Chemother 2009;64(2):317-25
25. Chiang WC, Nilsson M, Jensen PØ, et al. Extracellular DNA shields against aminoglycosides in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2013;57(5):2352-61
26. Mulcahy H, Charron-Mazenod L, Lewenza S. Extracellular DNA chelates cations and induces antibiotic resistance in pseudomonas aeruginosa biofilms. PLoS Pathog 2008;4:11
27. Walters MC, Roe F, Bugnicourt A, et al. Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob Agents Chemother 2003;47(1):317-23
28. Lewis K. Persister cells. Annu Rev Microbiol 2010;64:357-72
29. Mulet X, Moya B, Juan C, et al. Antagonistic interactions of Pseudomonas aeruginosa antibiotic resistance mechanisms in planktonic but not biofilm growth. Antimicrob Agents Chemother 2011;55(10): 4560-8
30. Whiteley M, Bangera MG, Bumgarner RE, et al. Gene expression in Pseudomonas aeruginosa biofilms. Nature 2001; 413(6858):860-4
31. Oliver A, Canton R, Campo P, et al. High frequency of hypermutable Pseudomonas aeruginosa in cystic fibrosis lung infection. Science 2000;288(5469):1251-4.
32. Macià MD, Blanquer D, Togores B, et al. Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections. Antimicrob Agents Chemother 2005;49(8):3382-6
33. Henrichfreise B, Wiegand I, Pfister W, Wiedemann B. Resistance mechanisms of multiresistant Pseudomonas aeruginosa strains from Germany and correlation with hypermutation. Antimicrob Agents Chemother 2007;51(11):4062-70.
34. Driffield K, Miller K, Bostock JM, et al. Increased mutability of Pseudomonas aeruginosa in biofilms. J Antimicrob Chemother 2008;61(5):1053-6
35. Boles BR, Singh PK. Endogenous oxidative stress produces diversity and adaptability in biofilm communities. Proc Natl Acad Sci USA 2008;105(34):12503-8
36. Bagge N, Hentzer M, Andersen JB, et al. Dynamics and spatial distribution of beta-lactamase expression in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2004;48(4):1168-74
37. Olivares J, Bernardini A, Garcia-Leon G, et al. The intrinsic resistome of bacterial pathogens. Front Microbiol 2013;4:103
38. Breidenstein EB, de la Fuente-Núñez C, Hancock RE. Pseudomonas aeruginosa: all roads lead to resistance. Trends Microbiol 2011;19(8):419-26
39. Blázquez J. Hypermutation as a factor contributing to the acquisition of antimicrobial resistance. Clin Infect Dis 2003;37(9):1201-9
40. Miller JH. Spontaneous mutators in bacteria: insights into pathways of mutagenesis and repair. Annu Rev Microbiol 1996;50:625-43
41. Rodriguez-Rojas A, Blázquez J. The Pseudomonas aeruginosa pfpI gene plays an antimutator role and provides general stress protection. J Bacteriol 2009;191(3):844-50
42. Z ? gur-Bertok D. DNA damage repair and bacterial pathogens. PLoS Pathog 2013; 9(11):e1003711
43. Blázquez J, Oliver A, Go-mez-Go-mez JM. Mutation and evolution of antibiotic resistance: antibiotics as promoters of antibiotic resistance? Curr Drug Targets 2002;3(4):345-9
44. Blázquez J, Go-mez-Go-mez JM, Oliver A, et al. PBP3 inhibition elicits adaptive responses in Pseudomonas aeruginosa. Mol Microbiol 2006;62(1):84-99
45. Pe-rez-Capilla T, Baquero MR, Go-mez-Go-mez JM, et al. SOS independent induction of dinB transcription by beta-lactam-mediated inhibition of cell wall synthesis in Escherichia coli. J Bacteriol 2005;187(4):1515-18
46. Oliver A. Mutators in cystic fibrosis chronic lung infection: prevalence, mechanisms, and consequences for antimicrobial therapy. Int J Med Microbiol 2010;300(8):563-72
47. Mena A, Smith EE, Burns JL, et al. Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation. J Bacteriol 2008;190(24):7910-17
48. Ciofu O, Riis B, Pressler T, et al. Occurence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation. Antimicrob Agents Chemother 2005;49(6):2276-82
49. Kenna DT, Doherty CJ, Foweraker J, et al. Hypermutability in environmental Pseudomonas aeruginosa and in populations causing pulmonary infection in individuals with cystic fibrosis. Microbiology 2007; 153(Pt 6):1852-9
50. Lo-pez-Causape-C, Rojo-Molinero E, Mulet X, et al. Clonal dissemination, emergence of mutator lineages and antibiotic resistance evolution in Pseudomonas aeruginosa cystic fibrosis chronic lung infection. PLoS One 2013; 8(8):e71001
51. Prunier AL, Malbruny B, Laurans M, et al. High rate of macrolide resistance in Staphylococcus aureus strains from patients with cystic fibrosis reveals high proportions of hypermutable strains. J Infect Dis 2003; 187(11):1709-16
52. Román F, Canto-n R, Pe-rez-Vázquez M, et al. Dynamics of long-term colonization of respiratory tract by Haemophilus influenzae in cystic fibrosis patients shows a marked increase in hypermutable strains. J Clin Microbiol 2004;42(4):1450-9
53. Del Campo R, Morosini MI, de la Pedrosa EG, et al. Population structure, antimicrobial resistance, and mutation frequencies of Streptococcus pneumoniae isolates from cystic fibrosis patients. J Clin Microbiol 2005;43(5): 2207-14
54. Turrientes MC, Baquero MR, Sánchez MB, et al. Polymorphic mutation frequencies of clinical and environmental Stenotrophomonas maltophilia populations. Appl Environ Microbiol 2010;76(6): 1746-58
55. Vidigal PG, Dittmer S, Steinmann E, et al. Adaptation of Stenotrophomonas maltophilia in cystic fibrosis: molecular diversity, mutation frequency and antibiotic resistance. Int J Med Microbiol 2014; 304(5-6):613-19
56. Martina P, Feliziani S, Juan C, et al. Hypermutation in Burkholderia cepacia complex is mediated by DNA mismatch repair inactivation and is highly prevalent in cystic fibrosis chronic respiratory infection. Int J Med Microbiol 2014;304(8):1182-91
57. Rodŕguez-Rojas A, Oliver A, Blázquez J. Intrinsic and environmental mutagenesis drive diversification and persistence of Pseudomonas aeruginosa in chronic lung infections. J Infect Dis 2012;205(1):121-7
58. Ferroni A, Guillemot D, Moumile K, et al. Effect of mutator P. aeruginosa on antibiotic resistance acquisition and respiratory function in cystic fibrosis. Pediatr Pulmonol 2009;44(8):820-5
59. Tazi A, Chapron J, Touak G, et al. Rapid emergence of resistance to linezolid and mutator phenotypes in Staphylococcus aureus isolates from an adult cystic fibrosis patient. Antimicrob Agents Chemother 2013;57(10):5186-8
60. Macià MD, Borrell N, Segura M, et al. Efficacy and potential for resistance selection of antipseudomonal treatments in a mouse model of lung infection by hypermutable Pseudomonas aeruginosa. Antimicrob Agents Chemother 2006;50(3):975-83
61. Plasencia V, Borrell N, Maciá MD, et al. Influence of high mutation rates on the mechanisms and dynamics of in vitro and in vivo resistance development to single or combined antipseudomonal agents. Antimicrob Agents Chemother 2007;51(7): 2574-81
62. Henrichfreise B, Wiegand I, Luhmer-Becker I, Wiedemann B. Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro. Antimicrob Agents Chemother 2007;51:3642-9
63. Mulet X, Maciá MD, Mena A, et al. Azithromycin in Pseudomonas aeruginosa biofilms: bactericidal activity and selection of nfxB mutants. Antimicrob Agents Chemother 2009;53(4):1552-60
64. Riera E, Macià MD, Mena A, et al. Anti-biofilm and resistance suppression activities of CXA-101 against chronic respiratory infection phenotypes of Pseudomonas aeruginosa strain PAO1. J Antimicrob Chemother 2010;65(7): 1399-404
65. Macià MD, Perez JL, Molin S, Oliver A. Dynamics of mutator and antibiotic-resistant populations in a pharmacokinetic/pharmacodynamic model of Pseudomonas aeruginosa biofilm treatment. Antimicrob Agents Chemother 2011;55(11):5230-7.
66. Pedersen SS, Koch C, Høiby N, Rosendal K. An epidemic spread of multiresistant Pseudomonas aeruginosa in a cystic fibrosis centre. J Antimicrob Chemother 1986;17(4):505-16
67. LiPuma JJ, Mortensen JE, Dasen SE, et al. Ribotype analysis of Pseudomonas cepacia from cystic fibrosis treatment centers. J Pediatr 1988;113(5):859-62
68. Johnson WM, Tyler SD, Rozee KR. Linkage analysis of geographic and clinical clusters in Pseudomonas cepacia infections by multilocus enzyme electrophoresis and ribotyping. J Clin Microbiol 1994;32(4): 924-30
69. Ledson MJ, Gallagher MJ, Corkill JE, et al. Cross infection between cystic fibrosis patients colonised with Burkholderia cepacia. Thorax 1998;53(5):432-6
70. Drevinek P, Mahenthiralingam E. Burkholderia cenocepacia in cystic fibrosis: epidemiology and molecular mechanisms of virulence. Clin Microbiol Infect 2010;16(7): 821-30
71. Fothergill JL, Walshaw MJ, Winstanley C. Transmissible strains of Pseudomonas aeruginosa in cystic fibrosis lung infections. Eur Respir J 2012;40(1):227-38.
72. Fluge G, Ojeniyi B, Høiby N, et al. Typing of Pseudomonas aeruginosa strains in Norwegian cystic fibrosis patients. Clin Microbiol Infect 2001;7(5):238-43
73. Parkins MD, Glezerson BA, Sibley CD, et al. Twenty-five-year outbreak of Pseudomonas aeruginosa infecting individuals with cystic fibrosis: identification of the prairie epidemic strain. J Clin Microbiol 2014;52(4):1127-35
74. Rolain JM, François P, Hernandez D, et al. Genomic analysis of an emerging multiresistant Staphylococcus aureus strain rapidly spreading in cystic fibrosis patients revealed the presence of an antibiotic inducible bacteriophage. Biol Direct 2009;4:1
75. Molina A, Del Campo R, Maíz L, et al. High prevalence in cystic fibrosis patients of multiresistant hospital-acquired methicillinresistant Staphylococcus aureus ST228-SCCmecI capable of biofilm formation. J Antimicrob Chemother 2008; 62(5):961-7
76. Elizur A, Orscheln RC, Ferkol TW, et al. Panton-Valentine Leukocidin-positive methicillin-resistant Staphylococcus aureus lung infection in patients with cystic fibrosis. Chest 2007;131(6):1718-25
77. Campana S, Cocchi P, Döring G, et al. Emergence of an epidemic clone of community-associated methicillin-resistant panton-valentine leucocidin-negative Staphylococcus aureus in cystic fibrosis patient populations. J Clin Microbiol 2007; 45(9):3146
78. Glikman D, Siegel JD, David MZ, et al. Complex molecular epidemiology of methicillin-resistant Staphylococcus aureus isolates from children with cystic fibrosis in the era of epidemic community-associated methicillin-resistant S aureus. Chest 2008; 133(6):381-7
79. Cocchi P, Cariani L, Favari F, et al. Molecular epidemiology of meticillin-resistant Staphylococcus aureus in Italian cystic fibrosis patients: a national overview. J Cyst Fibros 2011;10(6):407-11
80. Lim YW, Evangelista JS 3rd, Schmieder R, et al. Clinical insights from metagenomic analysis of sputum samples from patients with cystic fibrosis. J Clin Microbiol 2014; 52(2):425-37
81. Fancello L, Desnues C, Raoult D, Rolain JM. Bacteriophages and diffusion of genes encoding antimicrobial resistance in cystic fibrosis sputum microbiota. J Antimicrob Chemother 2011;66(11): 2448-54 . This study shows that phages in the CF sputum microbiota represent a reservoir of mobilizable genes associated with antimicrobial resistance.
82. Holden MT, Seth-Smith HM, Crossman LC, et al. The genome of Burkholderia cenocepacia J2315, an epidemic pathogen of cystic fibrosis patients. J Bacteriol 2009;191(1):261-77
83. Winstanley C, Langille MG, Fothergill JL, et al. Newly introduced genomic prophage islands are critical determinants of in vivo competitiveness in the Liverpool Epidemic Strain of Pseudomonas aeruginosa. Genome Res 2009;19(1):12-23
84. Neuwirth C, Freby C, Ogier-Desserrey A, et al. VEB-1 in Achromobacter xylosoxidans from cystic fibrosis patient. Emerg Infect Dis 2006;12(11):1737-9
85. Agarwal G, Kapil A, Kabra SK, et al. Characterization of Pseudomonas aeruginosa isolated from chronically infected children with cystic fibrosis in India. BMC Microbiol 2005;5:43
86. Pollini S, Fiscarelli E, Mugnaioli C, et al. Pseudomonas aeruginosa infection in cystic fibrosis caused by an epidemic metallo-blactamase-producing clone with a heterogeneous carbapenem resistance phenotype. Clin Microbiol Infect 2011; 17(8):1272-5
87. Cardoso O, Alves AF, Leitaõ R. Metallo-beta-lactamase VIM-2 in Pseudomonas aeruginosa isolates from a cystic fibrosis patient. Int J Antimicrob Agents 2008;31(4):375-9
88. Leaõ RS, Pereira RH, Folescu TW, et al. KPC-2 carbapenemase-producing Klebsiella pneumoniae isolates from patients with Cystic Fibrosis. J Cyst Fibros 2011;10(2): 140-2
89. McCaughey G, Gilpin DF, Elborn JS, Tunney MM. The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection. Expert Rev Respir Med 2013;7(4):385-96
90. Conway SP, Pond MN, Watson A, et al. Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis. Thorax 1997;52(11): 987-93
91. Drusano GL. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis 2007;45(Suppl 1):S89-95
92. Jumbe N, Louie A, Leary R, et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003;112(2): 275-85
93. Lang BJ, Aaron SD, Ferris W, et al. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with multiresistant strains of Pseudomonas aeruginosa. Am J Resp Crit Care Med 2000;162(6):2241-5
94. Aaron SD, Ferris W, Henry DA, et al. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med 2000;161(4 Pt 1): 1206-12
95. Aaron SD, Vandemheen KL, Ferris W, et al. Combination antibiotic susceptibility testing to treat exacerbations of cystic fibrosis associated with multiresistant bacteria: a randomised, double-blind, controlled clinical trial. Lancet 2005; 366(9484):463-71
96. Haja Mydin H, Corris PA, Nicholson A, et al. Targeted antibiotic prophylaxis for lung transplantation in cystic fibrosis patients colonised with Pseudomonas aeruginosa using multiple combination bactericidal testing. J Transplant 2012;2012:135738
97. Herrmann G, Yang L, Wu H, et al. Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa. J Infect Dis 2010;202(10):1585-92.
98. Pamp SJ, Gjermansen M, Johansen HK, Tolker-Nielsen T. Tolerance to the antimicrobial peptide colistin in Pseudomonas aeruginosa biofilms is linked to metabolically active cells, and depends on the pmr and mexAB-oprM genes. Mol Microbiol 2008;68(1):223-40.
99. Trapnell BC, McColley SA, Kissner DG, et al. Fosfomycin/tobramycin for inhalation in patients with cystic fibrosis with Pseudomonas airway infection. Am J Respir Crit Care Med 2012;185(2):171-8
100. Maciá MD, Mena A, Borrell N, et al. Increased susceptibility to colistin in hypermutable Pseudomonas aeruginosa strains from chronic respiratory infections. Antimicrob Agents Chemother 2007;51(12): 4531-2
101. Maciá MD, Borrell N, Pe-rez JL, Oliver A. Detection and susceptibility testing of hypermutable Pseudomonas aeruginosa strains with the Etest and disk diffusion. Antimicrob Agents Chemother 2004;48(7): 2665-72
102. Mandsberg LF, Ciofu O, Kirkby N, et al. Antibiotic resistance in Pseudomonas aeruginosa strains with increased mutation frequency due to inactivation of the DNA oxidative repair system. Antimicrob Agents Chemother 2009;53(6):2483-91
103. Mirakhur A, Gallagher MJ, Ledson MJ, et al. Fosfomycin therapy for multiresistant Pseudomonas aeruginosa in cystic fibrosis. J Cyst Fibros 2003;2(1):19-24
104. Morin JP, Olier B, Voitte G, Fillastre JP. Can fosfomycin reduce the nephrotoxicity of aminoglycosides? Pathol Biol 1984;32(5): 338-42
105. Ohtani I, Ohtsuki K, Aikawa T, et al. Protective effect of fosfomycin against aminoglycoside ototoxicity. ORL J Otorhinolaryngol Relat Spec 1985;47(1): 42-8
106. Cabot G, Bruchmann S, Mulet X, et al. Pseudomonas aeruginosa ceftolozane-tazobactam resistance development requires multiple mutations leading to overexpression and structural modification of AmpC. Antimicrob Agents Chemother 2014;58(6):3091-9
107. Hornsey M, Phee L, Stubbings W, Wareham DW. In vitro activity of the novel monosulfactam BAL30072 alone and in combination with meropenem versus a diverse collection of important Gram-negative pathogens. Int J Antimicrob Agents 2013;42(4):343-6
108. Moskowitz SM, Foster JM, Emerson J, Burns JL. Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J Clin Microbiol 2004;42(5): 1915-22 .
109. Skindersoe ME, Alhede M, Phipps R, et al. Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa. Antimicrob Agents Chemother 2008;52(10):3648-63
110. Saiman L, Chen Y, Gabriel PS, Knirsch C. Synergistic activities of macrolide antibiotics against Pseudomonas aeruginosa, Burkholderia cepacia, Stenotrophomonas maltophilia, and Alcaligenes xylosoxidans isolated from patients with cystic fibrosis. Antimicrob Agents Chemother 2002;46(4): 1105-7
111. Hengzhuang W, Ciofu O, Yang L, et al. High b-lactamase levels change the pharmacodynamics of b-lactam antibiotics in Pseudomonas aeruginosa biofilms. Antimicrob Agents Chemother 2013;57(1): 196-204 . First study demonstrating that pharmacokinetic/pharmacodynamic parameters may differ significantly in conventional (planktonic) and biofilm-based therapeutic models.
112. Alkawash MA, Soothill JS, Schiller NL. Alginate lyase enhances antibiotic killing of mucoid Pseudomonas aeruginosa in biofilms. APMIS 2006;114(2):131-8
113. Moons P, Werckx W, Van Houdt R, et al. Resistance development of bacterial biofilms against bacteriophage attack. Commun Agr Appl Biol Sci 2006;71(1):297-300
114. Morello E, Saussereau E, Maura D, et al. Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS One 2011;6(2):e16963
115. Saussereau E, Vachier I, Chiron R, et al. Effectiveness of bacteriophages in the sputum of cystic fibrosis patients. Clin Microbiol Infect 2014. [Epub ahead of print]
116. Kaneko Y, Thoendel M, Olakanmi O, et al. The transition metal gallium disrupts Pseudomonas aeruginosa iron metabolism and has antimicrobial and antibiofilm activity. J Clin Invest 2007;117(4):877-88
117. Garc?á-Contreras R, Lira-Silva E, Jasso-Chávez R, et al. Isolation and characterization of gallium resistant Pseudomonas aeruginosa mutants. Int J Med Microbiol 2013;303(8):574-82
118. Singh PK, Parsek MR, Greenberg EP, Welsh MJ. A component of innate immunity prevents bacterial biofilm development. Nature 2002;417(6888):552-5
119. Ciofu O, Bagge N, Høiby N. Antibodies against beta-lactamase can improve ceftazidime treatment of lung infection with beta-lactam-resistant Pseudomonas aeruginosa in a rat model of chronic lung infection. APMIS 2002;110(12):881-91
120. Jakobsen TH, Bjarnsholt T, Jensen PØ, et al. Targeting quorum sensing in Pseudomonas aeruginosa biofilms: current and emerging inhibitors. Future Microbiol 2013;8(7):901-21 .
121. Garc?á-Contreras R, Nuñez-Lo-pez L, Jasso-Chávez R, et al. Quorum sensing enhancement of the stress response promotes resistance to quorum quenching and prevents social cheating. ISME J 2014. [Epub ahead of print]
122. Kalia VC, Wood TK, Kumar P. Evolution of resistance to quorum-sensing inhibitors. Microb Ecol 2014;68(1):13-23
123. Davies DG, Marques CN. A fatty acid messenger is responsible for inducing dispersion in microbial biofilms. J Bacteriol 2009;191(5):1393-403
124. Barraud N, Hassett DJ, Hwang SH, et al. Involvement of nitric oxide in biofilm dispersal of Pseudomonas aeruginosa. J Bacteriol 2006;188(21):7344-53
125. Gjermansen M, Ragas P, Tolker-Nielsen T. Proteins with GGDEF and EAL domains regulate Pseudomonas putida biofilm formation and dispersal. FEMS Microbiol Lett 2006;265(2):215-24
126. Rogers SA, Huigens RW 3rd, Cavanagh J, Melander C. Synergistic effects between conventional antibiotics and 2-aminoimidazole-derived antibiofilm agents. Antimicrob Agents Chemother 2010;54(5):2112-18
127. Saiman L, Siegel JD, LiPuma JJ, et al. Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect Control Hosp Epidemiol 2014;35(Suppl 1): S1-S67